Breaking news
New Products Posted to GenomeWeb: BD Biosciences, Thermo Fisher Scientific, Yourgene Health, GeneDx
New products and services recently posted on GenomeWeb.
Autism Study Finds Similar Rare, De Novo Risk Contributions in Males, Females
Researchers saw similar genetic liability linked to inherited rare or de novo mutations in males and females with autism spectrum disorder, despite sex-biased ASD diagnoses.
In Brief This Week: Qiagen, Devyser Diagnostics, Sequential Skin, Amili, TruDiagnostic
News items for the week of Feb. 10, 2025.
Tempus, IFLI Partner to Accelerate Development of Follicular Lymphoma Therapies
The collaboration will involve making a real-world multimodal dataset available in Tempus' Lens platform that researchers can use to accelerate treatment development.
GenomOncology, Pillar Biosciences Partner to Develop NGS-Driven Clinical Decision Support Solution
In the deal, GenomOncology will integrate Pillar's RUO NGS panels into its clinical decision support platform to enable personalized cancer treatment insights.
Latent Labs Emerges From Stealth With $50M in Funding for AI-Powered Protein Design
The firm is developing generative AI software to speed drug discovery through de novo protein design.
QuidelOrtho Q4 Revenues Dip 5 Percent, Beat Estimates
For 2025, the company guided to total revenues of $2.60 billion to $2.81 billion and adjusted EPS of $2.07 to $2.57.
Grail Stock Surges on Quest Diagnostics Integration of Galleri MCED Test
Physicians in the US can now order the blood-based multi-cancer early detection assay through Quest.
Cell-Free DNA Analysis Predicts Preeclampsia Risk
Researchers used a new computational framework to predict preeclampsia risk from low-coverage whole-genome sequences generated on cell-free DNA found in maternal blood.
Waters Q4 Revenues Rise 6 Percent
The company's Q4 revenues were $872.7 million versus $819.5 million in Q4 2023 and above the consensus Wall Street estimate of $856.9 million.